Clinical trials: Overall Mortality
HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
Primary liver cancer is a malignant tumor with a very poor prognosis. Hepatocellular carcinoma(HCC) accounts for approximately 80% of cases.
- Conditions
- HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine, ICG (Indocyanine Green), Overall Survival (All-cause Mortality)
- Trial name
- DAWNbreak-120 (NCT07691645)
- Testing
- Shuganhuazhuo Formula, Targeted therapy, Immunotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xiang-Qian
Overall Survival (All-cause Mortality)
Exercise and Mortality in Middle-Aged and Older Adults
This protocol is a retrospective study using the observational data of the the Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial with over 150,000 participants aged 55-74 years to conduct a target trial emulation to…
- Trial name
- NCT07224659
- Testing
- Control, Exercise
- Where
- United States
- Volunteers
- 19,000 people
- Sponsor
- City of Hope Medical Center
Gastric Cancer, Mortality of Gastric Cancer
Predictive Factors of Morbidity and Mortality and Overall Survival of Patients With Gastric Cancer : a Case Series
This is a retrospective study extending over a period of three years concerning patients with gastric adenocarcinoma hospitalized in the digestive cancer surgery and liver transplant service of the IBN ROCHD University Hospital…
- Conditions
- Gastric Cancer, Mortality of Gastric Cancer, Overall Survival of Patients With Gastric Cancer
- Trial name
- NCT05186402
- Testing
- Total or subtotal gastrectomy
- Volunteers
- 80 people
- Sponsor
- Sylvestre KABURA
Overall Mortality
Retrospective Follow-up of BIOLUX P-I/-II
The aim is to collect long-term clinical data from 132 patients from Belgium, Germany and Austria who had previously participated in either of the BIOLUX P-I or P-II studies.
- Trial name
- NCT04250909
- Testing
- Passeo-18, Passeo-18 Lux
- Where
- 8 sites in Austria, Belgium and 1 more
- Volunteers
- 132 people
- Sponsor
- Biotronik AG
Blood Pressure, Cardiovascular Risk Factor
Non-Invasive Aortic Ambulatory Blood Pressure Monitoring for The Detection of Target Organ Damage in The Chinese Population
This study is a sub-investigation of SAFAR study. Consecutive patients with established hypertension (treated or untreated with antihypertensive drugs) or with suspected hypertension are recruited and their 24-hour brachial and…
- Conditions
- Blood Pressure, Cardiovascular Risk Factor, Target Organ Damage, Cardiovascular Events
- Trial name
- SAFAR-China (NCT03154203)
- Testing
- No intervention in this study
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Shanghai 10th People's Hospital